Performance of the German version of the PARCA-R questionnaire as a developmental screening tool in two-year-old very preterm infants

Picotti, Eleonora; Bechtel, Nina; Latal, Beatrice; Borradori-Tolsa, Cristina; Graz, Myriam Bickle; Grunt, Sebastian; Johnson, Samantha; Wolke, Dieter; Natalucci, Giancarlo

doi:10.1371/journal.pone.0236289

Cited by 8 publications

(3 citation statements)

References 28 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To analyse the neurocognitive and motor outcome of preterm infants at the corrected age of 2 years, the PARCA-R questionnaire [4][5][6] was used in the GNN cohort.…”

Section: Parca-r Datamentioning

confidence: 99%

Observational study on the neonatal outcome during the COVID‐19 pandemic in Germany

et al. 2023

View full text Add to dashboard Cite

AimWe aimed to determine stillbirth, preterm birth, perinatal complications, and the developmental outcome of children born preterm during the COVID‐19 pandemic in Germany.MethodsNational data from the perinatal survey of preterm and term infants born in 2017–2020 between 22 March and 31 December were evaluated. Neurodevelopment of preterm infants at 2 years corrected age was tested with the Parent Report of Children's Abilities‐Revised questionnaire and by clinical testing with Bayley scales, either before or during the COVID‐19 pandemic. Statistical significance was calculated using a Pearson's chi‐square‐independence test and a linear regression model.ResultsIn 2020, there was an increase of stillbirths of 0.02% (p = 0.01) and a decrease in preterm births by 0.38% (p < 0.001). No changes were found in a representative subgroup of infants with regard to neurodevelopmental scores (mental developmental index and psychomotor developmental index) or in parent survey data (non‐verbal cognition scale and language development scale).ConclusionIncreasing rates of stillbirths and decreasing preterm births in Germany were observed. Existing networks might stabilise neurodevelopment of preterm infants during the COVID‐19 pandemic.

show abstract

“…To analyse the neurocognitive and motor outcome of preterm infants at the corrected age of 2 years, the PARCA-R questionnaire [4][5][6] was used in the GNN cohort.…”

Section: Parca-r Datamentioning

confidence: 99%

Observational study on the neonatal outcome during the COVID‐19 pandemic in Germany

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For this study, an online platform will be developed, where parents of the participating children will be invited to complete the non-verbal cognitive part of the PARCA-R questionnaire, in their respective languages. This typically takes less than 10 min to complete [ 27 ]. The full PARCA-R will not be used, since a validated language component is not available in all countries; PARCA-R has only been standardised for use in the UK.…”

Section: Methodsmentioning

confidence: 99%

Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial

Rasmussen,

Hansen,

Pellicer

et al. 2023

Trials

View full text Add to dashboard Cite

Background In the SafeBoosC-III trial, treatment guided by cerebral oximetry monitoring for the first 72 hours after birth did not reduce the incidence of death or severe brain injury in extremely preterm infants at 36 weeks’ postmenstrual age, as compared with usual care. Despite an association between severe brain injury diagnosed in the neonatal period and later neurodevelopmental disability, this relationship is not always strong. The objective of the SafeBoosC-III follow-up study is to assess mortality, neurodevelopmental disability, or any harm in trial participants at 2 years of corrected age. One important challenge is the lack of funding for local costs for a trial-specific assessment. Methods Of the 1601 infants randomised in the SafeBoosC-III trial, 1276 infants were alive at 36 weeks’ postmenstrual age and will potentially be available for the 2-year follow-up. Inclusion criteria will be enrollment in a neonatal intensive care unit taking part in the follow-up study and parental consent if required by local regulations. We aim to collect data from routine follow-up programmes between the ages of 18 and 30 months of corrected age. If no routine follow-up has been conducted, we will collect informal assessments from other health care records from the age of at least 12 months. A local co-investigator blinded to group allocation will classify outcomes based on these records. We will supplement this with parental questionnaires including the Parent Report of Children’s Abilities—Revised. There will be two co-primary outcomes: the composite of death or moderate or severe neurodevelopmental disability and mean Bayley-III/IV cognitive score. We will use a 3-tier model for prioritisation, based on the quality of data. This approach has been chosen to minimise loss to follow-up assuming that little data is better than no data at all. Discussion Follow-up at the age of 2 years is important for intervention trials in the newborn period as only time can show real benefits and harms later in childhood. To decrease the risk of generalisation and data-driven biased conclusions, we present a detailed description of the methodology for the SafeBoosC-III follow-up study. As funding is limited, a pragmatic approach is necessary. Trial registration ClinicalTrials.gov NCT05134116. Registered on 24 November 2021.

show abstract

“…For this study, an online platform will be developed, where parents of the participating children will be invited to complete the non-verbal cognitive part of the PARCA-R questionnaire, in their respective languages. This typically takes less than 10 minutes to complete (27). The full PARCA-R will not be used, since a validated language component is not available in all countries; PARCA-R has only been standardised for use in the United Kingdom.…”

Section: Parca-rmentioning

confidence: 99%

Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the two-year follow up of the SafeBoosC-III randomised clinical trial

Rasmussen

Hansen

Pellicer

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In the SafeBoosC-III trial, treatment guided by cerebral oximetry monitoring for the first 72 hours after birth did not reduce the incidence of death or severe brain injury in extremely preterm infants at 36 weeks’ postmenstrual age, as compared with usual care. Despite an association between severe brain injury diagnosed in the neonatal period and later neurodevelopmental disability, this relationship is not always strong. The objective of the SafeBoosC-III follow-up study is to assess mortality, neurodevelopmental disability or any harms in trial participants at two years of corrected age. One important challenge is lack of funding for local costs for a trial-specific assessment. Methods: Of the 1601 infants randomised in the SafeBoosC-III trial, 1276 infants were alive at 36 weeks’ postmenstrual age and will potentially be available for the two-year follow up. Inclusion criteria will be enrollment in a neonatal intensive care unit taking part in the follow-up studyand parental consent if required by local regulations. We aim to collect data from routine follow up programs between the age of 18 to 30 months of corrected age. If no routine follow up has been conducted, we will collect informal assessments from other health care records from the age of at least 12 months. A local co-investigator blinded to group allocation will classify outcomes based on these records. We will supplement this with parental questionnaires including the Parent Report of Children’s Abilities - Revised. There will be two co-primary outcomes: the composite of death or moderate-or-severe neurodevelopmental disability; and mean Bayley-III/IV cognitive score. We will use a 3-tier model for prioritisation, based on the quality of data. This approach has been chosen to minimise loss-to-follow up assuming that little data is better than no data at all. Discussion: Follow up at the age of two years is important for intervention trials in the newborn period as only time can show real benefits and harms later in childhood. To decrease the risk of generalisation and data driven biased conclusions, we present a detailed description of the methodology for the SafeBoosC-III follow up study. As funding is limited, a pragmatic approach is necessary. Study registration: ClinicalTrial.gov NCT05134116 (registered 24-11 2021), https://clinicaltrials.gov/ct2/show/NCT05134116?term=safeboosc&draw=2&rank=2 Protocol version 1 (1st of May 2023)

show abstract

Performance of the German version of the PARCA-R questionnaire as a developmental screening tool in two-year-old very preterm infants

Cited by 8 publications

References 28 publications

Observational study on the neonatal outcome during the COVID‐19 pandemic in Germany

Observational study on the neonatal outcome during the COVID‐19 pandemic in Germany

Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial

Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the two-year follow up of the SafeBoosC-III randomised clinical trial

Contact Info

Product

Resources

About